Salvage Concurrent Chemo-radiation Therapy for Loco-regional Recurrence Following Curative Surgery of Non-small Cell Lung Cancer
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose This study is to report clinical outcomes of salvage concurrent chemo-radiation therapy (CCRT) in treating patients with loco-regional recurrence (LRR) following initial complete resection of non-small cell lung cancer. Materials and Methods Between February 2004 and December 2016, 127 patients underwent salvage CCRT for LRR. The median radiation therapy (RT) dose was 66 Gy and clinical target volume (CTV) was to cover recurrent lesion with margin without elective inclusion of regional lymphatics. Majority of patients (94.5%) received weekly platinum-based doublet chemotherapy during RT course. Results The median follow-up time from the start of CCRT was 25 months. The median survival duration was 49 months, and overall survival (OS) rates at 2 and 5 years were 72.9% and 43.9%. The 2- and 5-year rates of in-field failure-free survival, distant metastasis free survival, and progression free survival were 82.4% and 73.8%, 50.4% and 39.9%, and 34.6% and 22.3%, respectively. Grade 3 radiation-related esophagitis and pneumonitis occurred in 14 (11.0%) and six patients (4.7%), respectively. On both univariate and multivariate analysis, higher biologically equivalent dose (BED10) ( 79.2 Gy10 vs. < 79.2 Gy10; hazard ratio [HR], 0.431), smaller CTV ( 80 cm3 vs. > 80 cm3; HR, 0.403), and longer disease-free interval (> 1 year vs. 1 year; HR, 0.489) were significantly favorable factors for OS. Conclusion The current study has demonstrated that high dose salvage CCRT focused to the involved lesion only was highly effective and safe. In particular, higher BED10, smaller CTV, and longer disease-free interval were favorable factors for improved survival.
Abstract
Purpose This study is to report clinical outcomes of salvage concurrent chemo-radiation therapy (CCRT) in treating patients with loco-regional recurrence (LRR) following initial complete resection of non-small cell lung cancer. Materials and Methods Between February 2004 and December 2016, 127 patients underwent salvage CCRT for LRR. The median radiation therapy (RT) dose was 66 Gy and clinical target volume (CTV) was to cover recurrent lesion with margin without elective inclusion of regional lymphatics. Majority of patients (94.5%) received weekly platinum-based doublet chemotherapy during RT course. Results The median follow-up time from the start of CCRT was 25 months. The median survival duration was 49 months, and overall survival (OS) rates at 2 and 5 years were 72.9% and 43.9%. The 2- and 5-year rates of in-field failure-free survival, distant metastasis free survival, and progression free survival were 82.4% and 73.8%, 50.4% and 39.9%, and 34.6% and 22.3%, respectively. Grade 3 radiation-related esophagitis and pneumonitis occurred in 14 (11.0%) and six patients (4.7%), respectively. On both univariate and multivariate analysis, higher biologically equivalent dose (BED10) ( 79.2 Gy10 vs. < 79.2 Gy10; hazard ratio [HR], 0.431), smaller CTV ( 80 cm3 vs. > 80 cm3; HR, 0.403), and longer disease-free interval (> 1 year vs. 1 year; HR, 0.489) were significantly favorable factors for OS. Conclusion The current study has demonstrated that high dose salvage CCRT focused to the involved lesion only was highly effective and safe. In particular, higher BED10, smaller CTV, and longer disease-free interval were favorable factors for improved survival.
참고문헌 (30)
- Ferlay J, "Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012", Int J Cancer, 136, pp.E359~E386 (2015)
- 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2014", Cancer Research and Treatment, 49(2), pp.292~305 (2017), 대한암학회
- al-Kattan K, "Disease recurrence after resection for stage I lung cancer", Eur J Cardiothorac Surg, 12, pp.380~384 (1997)
- Williams BA, "Predicting postrecurrence survival among completely resected nonsmall-cell lung cancer patients", Ann Thorac Surg, 81, pp.1021~1027 (2006)
- Sugimura H, "Survival after recurrent nonsmall-cell lung cancer after complete pulmonary resection", Ann Thorac Surg, 83, pp.409~417 (2007)
- Saisho S, "Post-recurrence survival of patients with non-small-cell lung cancer after curative resection with or without induction", adjuvant chemotherapy, 2013, pp.16, 166~172
- Lee J, "Recurrence dynamics after trimodality therapy(Neoadjuvant concurrent chemoradiotherapy and surgery)in patients with stage IIIA(N2)lung cancer", Lung Cancer, 115, pp.89~96 (2018)
- Sonobe M, "Identification of subsets of patients with favorable prognosis after recurrence in completely resected non-small cell lung cancer", Ann Surg Oncol, 21, pp.2546~2554 (2014)
- Yano T, "Therapeutic strategy for postoperative recurrence in patients with nonsmall cell lung cancer", World J Clin Oncol, 5, pp.1048~1054 (2014)
- Terzi A, "Completion pneumonectomy for non-small cell lung cancer : experience with 59 cases", Eur J Cardiothorac Surg, 22, pp.30~34 (2002)
- Hyoung Soo Kim, "Surgical Resection of Recurrent Lung Cancer in Patients Following Curative Resection", Journal of Korean Medical Science, 21(2), pp.224~228 (2006), 대한의학회
- Kelsey CR, "Local recurrence following initial resection of NSCLC : salvage is possible with radiation therapy", Cancer J, 12, pp.283~288 (2006)
- Tada T, "Non-small cell lung cancer : radiation therapy for locoregional recurrence after complete resection", Int J Clin Oncol, 10, pp.425~428 (2005)
- Cai XW, "Comparative survival in patients with postresection recurrent versus newly diagnosed non-small-cell lung cancer treated with radiotherapy", Int J Radiat Oncol Biol Phys, 76, pp.1100~1105 (2010)
- 배선현, "High Dose Involved Field Radiation Therapy as Salvage for Loco-Regional Recurrence of Non-Small Cell Lung Cancer", Yonsei Medical Journal, 53(6), pp.1120~1127 (2012), 연세대학교의과대학[DOI]
- Bar J, "Chemoradiotherapy for locoregional recurrence of non-smallcell lung cancer after surgical resection : a retrospective analysis", Clin Lung Cancer, 14, pp.200~204 (2013)
- Lee NK, "Prognostic value of gross tumor volume for definitive radiation therapy in patients with locoregionally recurrent nonsmall-cell lung cancer after surgical resection", Clin Lung Cancer, 14, pp.399~406 (2013)
- 김은지, "Long-term outcomes after salvage radiotherapy for postoperative locoregionally recurrent non-small-cell lung cancer", Radiation oncology journal, 35(1), pp.55~64 (2017), 대한방사선종양학회
- Seol KH, "Salvage radiotherapy for regional lymph node oligo-recurrence after radical surgery of non-small cell lung cancer", Thorac Cancer, 8, pp.620~629 (2017)
- Okawara G, "Management of unresected stage III nonsmall cell lung cancer: a systematic review", J Thorac Oncol, 1, pp.377~393 (2006)
- O'Rourke N, "Concurrent chemoradiotherapy in non-small cell lung cancer", Cochrane Database Syst Rev, (6), pp.CD002140~ (2010)
- van Tinteren H, "Effectiveness of positron emission tomography in the preoperative assessment of patients with suspected non-small-cell lung cancer : the PLUS multicentre randomised trial", Lancet, 359, pp.1388~1393 (2002)
- Bar-Shalom R, "Clinical performance of PET", CT in evaluation of cancer : additional value for diagnostic imaging and patient management, 2003, pp.44, 1200~1209
- Berghmans T, "Primary tumor standardized uptake value (SUVmax) measured on fluorodeoxyglucose positron emission tomography (FDG-PET) is of prognostic value for survival in non-small cell lung cancer (NSCLC): a systematic review and meta-analysis (MA) by the European Lung Cancer Working Party for the IASLC Lung Cancer Staging Project", J Thorac Oncol, 3, pp.6~12 (2008)
- Paesmans M, "Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer : update of a systematic review and metaanalysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project", J Thorac Oncol, 5, pp.612~619 (2010)
- Jimenez-Bonilla JF, "Diagnosis of recurrence and assessment of post-recurrence survival in patients with extracranial non-small cell lung cancer evaluated by 18F-FDG PET", CT, 2013, pp.81, 71~76
- Dosoretz DE, "Local control in medically inoperable lung cancer : an analysis of its importance in outcome and factors determining the probability of tumor eradication", Int J Radiat Oncol Biol Phys, 27, pp.507~516 (1993)
- Kong FM, "High-dose radiation improved local tumor control and overall survival in patients with inoperable", unresectable non-small-cell lung cancer : long-term results of a radiation dose escalation study, 2005, pp.63, 324~333
- Bradley JD, "Standard-dose versus high-dose conformal radiotherapy with concurrent and consolidation carboplatin plus paclitaxel with or without cetuximab for patients with stage IIIA or IIIB non-small-cell lung cancer(RTOG 0617) : a randomised, two-by-two factorial phase 3 study", Lancet Oncol, 16, pp.187~199 (2015)
- Jegadeesh N, "Evaluating intensity-modulated radiation therapy in locally advanced non-small-cell lung cancer : results from the national cancer data base", Clin Lung Cancer, 17, pp.398~405 (2016)